Interim findings from the DASL-HiCaP trial (ANZUP 1801), jointly led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) and the Sydney Clinical Trials Centre (formerly the NHMRC Clinical Trials Centre) at the University of Sydney report that adding darolutamide (Nubeqa®), an oral androgen receptor inhibitor, to standard of care for this population, decreases the risk of spread of prostate cancer in people affected with very high-risk localised or locally advanced prostate cancer.1 The findings have been presented in a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress (23-27 October) in Madrid on 24 October by the study global co-chair Associate Professor Tamim Niazi, signifying the global significance and practice changing implications of this study for prostate cancer treatment and patient outcomes.
Approximately 28,800 Australians are diagnosed with prostate cancer each year.2 Around 38% are diagnosed with high-risk, very-high-risk, or advanced disease, representing approximately 10,900 people annually.2 People with very high-risk localised or locally advanced prostate cancer remain at risk of their cancer returning or spreading despite current treatment approaches.2
Current standard treatment for people affected by prostate cancer that has not spread beyond the pelvis combines radiation therapy with androgen deprivation therapy (ADT), which lowers testosterone levels. While this approach improves outcomes, there remains a need for new treatment strategies that can further reduce the risk of disease progression.
The DASL-HiCaP trial investigated whether adding an oral androgen receptor inhibitor (darolutamide) to this standard treatment could decrease the risk of the cancer spreading to other parts of the body.¹ The trial’s primary endpoint was metastasis-free survival, defined as the time from the start of treatment until cancer recurrence or spread was detected on standard scans, or death from any cause.¹
According to this positive analysis, participants who received darolutamide experienced longer metastasis-free survival than those who received placebo.¹ The analysis also observed fewer prostate cancer deaths and fewer patients in whom their prostate-specific antigen (PSA) levels rose, indicating a recurrence.¹ These results, from the first planned analysis of the trial, establish the trial’s main finding. Follow-up of participants is continuing to provide further information on longer-term outcomes, including overall survival, with a further analysis planned when approximately 130 metastasis-free survival events have occurred.
Professor Christopher Sweeney, DASL-HiCaP Study co-Chair, Professor of Medicine and Director of SAiGENCI, Adelaide University.
said, “These findings show that adding darolutamide to standard radiation therapy and hormone therapy reduces the risk of cancer recurring in people with a very high-risk prostate cancer. From prior work we know major decreases in recurrences ultimately leads to a decreased chance of dying from prostate cancer. We will therefore continue the study to detail the impact on long term survival. We look forward to presenting the full results of the first analysis at ESMO and discussing their implications with the international medical community.”
The DASL-HiCaP trial was jointly led by ANZUP and the Sydney Clinical Trials Centre (formerly the NHMRC Clinical Trials Centre), in collaboration with the Canadian Cancer Trials Group, Cancer Trials Ireland, Memorial Sloan Kettering Cancer Center, and the Prostate Cancer Clinical Trials Consortium in the US and funded by Bayer
Australian and New Zealand Urogenital and Prostate Cancer Trials Group Chairman, Professor Ian Davis said, “A diagnosis of very high-risk local and locally advanced prostate cancer can be confronting for patients and their families, particularly given the risk of the cancer returning or spreading despite treatment. These findings are encouraging and contribute to our understanding of how outcomes for people affected by this disease may be improved. We are grateful to the participants who volunteered for the trial and to the researchers and clinicians whose collaboration made this international study possible.”
To learn more about ANZUP’s mission to improve the lives of those affected by bladder, kidney, testicular, penile and prostate cancers, visit anzup.org.au.
ENDS
Issued on behalf of Australian and New Zealand Urogenital and Prostate Cancer Trials Group by HAVAS Red. For further information, please contact: Isabelle Sinnott
M: 0493 286 142 / E: isabelle.sinnott@havasred.com.
About DASL-HiCaP trial (ANZUP 1801)
The DASL-HiCaP trial is investigator-initiated and one of the largest of its kind, enrolling 1,106 participants across Australia, New Zealand, Canada, the United States, Ireland and the United Kingdom. It is an international, randomised, placebo-controlled, double-blind study. All participants received state-of-the-art standard treatment (radiation therapy plus ADT) and were then randomly assigned to also receive either the study medicine or an identical placebo tablet. The trial has closed to recruitment, and participants will continue to be followed over the longer term.
About ANZUP
ANZUP (https://www.anzup.org.au) is the leading cancer-cooperative trials group bringing together all of the professional disciplines and groups involved in researching and treating urogenital cancers to conduct high-quality cancer research. ANZUP’s mission is to improve the lives of people affected by bladder, kidney, testicular, penile, and prostate cancers, towards a vision of living life without fear of cancer. ANZUP identifies gaps in evidence and areas of clinical need, collaborates with the best clinicians and researchers in genitourinary cancer and communicates frequently and effectively with the broader community along the way. ANZUP receives valuable infrastructure support from the Australian Government through Cancer Australia and research funding from Prostate Cancer Foundation of Australia.
About the Sydney Clinical Trials Centre
The Sydney Clinical Trials Centre is a flagship research centre of the Faculty of Medicine and Health at the University of Sydney that designs and manages clinical trials. This includes responsibility for study coordination, monitoring, data acquisition and management and statistical analysis. The Sydney Clinical Trials Centre has health economics, biostatistics, systematic reviews and biomarker teams work with trial data and inform healthcare providers about best practice. For further details, please visit its website at https://www.ctc.usyd.edu.au
References
- Niazi T et al, Darolutamide with androgen-deprivation therapy and definitive or salvage radiation therapy for localised, very high-risk prostate cancer: an international, placebo-controlled, randomised phase 3 trial (DASL-HiCAP; ANZUP 1801). Abstract accepted for presentation in a Presidential Symposium at: European Society for Medical Oncology (ESMO) Congress 2026; 23-27 Oct 2026; Madrid, Spain.
- Prostate Cancer Foundation of Australia. Facts and Figures. Available at. https://www.prostate.org.au/risk-and-symptoms/facts-figures/. Accessed August 2026.